Abstract: A cooking apparatus is provided. The cooking apparatus includes a main body comprising a cooking chamber, a first heat source disposed in the cooking chamber to generate radiant heat, a second heat source disposed in the cooking chamber to generate convection heat, a microwave radiator configured to generate microwaves inside the cooking chamber, an electrical component room partitioned from the cooking chamber and provided to receive the microwave radiator, a cooling fan configured to draw in outside air and discharge the outside air to the electrical component room so as to cool the electrical component room, a guide duct provided to guide air discharged from the cooling fan into the cooking chamber, and an opening and closing device configured to open and close the guide duct.

Abstract: The present invention relates to a composition for preventing or treating neurodegenerative diseases. The pharmaceutical composition of the present invention contains at least two selected from the group consisting of an interleukin 10 (IL-10) protein or a gene encoding the same, a glial cell line-derived neurotrophic factor (GDNF) protein or a gene encoding the same, and a glutamate decarboxylase (GAD) protein or a gene encoding the same. Since the pharmaceutical composition of the present invention exhibits a better effect of alleviating and preventing neurodegenerative diseases by co-administration of active ingredients than upon single administration, the pharmaceutical composition of the present invention can exhibit the same or higher effect only with a low concentration of the active ingredients. Therefore, the pharmaceutical composition of the present invention can be advantageously used for the prevention or treatment of neurodegenerative diseases.

Abstract: Provided is a non-aqueous electrolyte solution for a lithium secondary battery containing a lithium salt, an organic solvent and a phosphoric acid-based additive of Formula 1 below, which significantly improves the high temperature stability of the lithium secondary battery: wherein R is described herein.

Abstract: Provided is a non-aqueous electrolyte solution for a lithium secondary battery containing a lithium salt, an organic solvent and a phosphoric acid-based additive of Formula 1 below, which significantly improves the high temperature stability of the lithium secondary battery: wherein R is described herein.

Abstract: A non-aqueous electrolyte solution for a lithium secondary battery and a lithium secondary battery including the same are disclosed herein. In some embodiments, a non-aqueous electrolyte solution includes a lithium salt, an organic solvent, and a phosphoric acid-based additive represented by Formula 1 below, which improves the high temperature stability in a lithium secondary battery: wherein R is described herein.

Abstract: Provided is a non-aqueous electrolyte solution for a lithium secondary battery containing a lithium salt, an organic solvent and a phosphoric acid-based additive of Formula 1 below, which significantly improves the high temperature stability of the lithium secondary battery: wherein R is described herein.

Abstract: A non-aqueous electrolyte solution for a lithium secondary battery and a lithium secondary battery including the same are disclosed herein. In some embodiments, a non-aqueous electrolyte solution includes a lithium salt, an organic solvent and a phosphoric acid-based additive represented by Formula 1 below, which improves the high temperature stability in a lithium secondary battery: wherein R is described herein.

Abstract: A non-aqueous electrolyte solution for a lithium secondary battery and a lithium secondary battery including the same are disclosed herein. In some embodiments, a non-aqueous electrolyte solution includes a lithium salt, an organic solvent, and a phosphoric acid-based additive-represented by Formula 1 below, which improves the high temperature stability in a lithium secondary battery: wherein R is described herein.

Abstract: Provided is a non-aqueous electrolyte solution for a lithium secondary battery containing a lithium salt, an organic solvent, and a phosphoric acid-based additive of Formula 1 below, which significantly improves the high temperature stability of the lithium secondary battery: wherein R is described herein.

Abstract: A non-aqueous electrolyte solution for a lithium secondary battery and a lithium secondary battery including the same are disclosed herein. In some embodiments, a non-aqueous electrolyte solution includes a lithium salt, an organic solvent, and a phosphoric acid-based additive represented by Formula 1 below, which improves the high temperature stability in a lithium secondary battery: wherein R is described herein.

Abstract: A light-emitting device includes: a first electrode; a second electrode facing the first electrode; an interlayer between the first electrode and the second electrode; and an organometallic compound of Formula 1: wherein Formula 1 is the same as described in the specification. The organometallic compound satisfies at least one of Conditions 1 or 2: Condition 1 the organometallic compound has a dipole moment of 3 Debye or less; and Condition 2 the organometallic compound has a horizontal orientation ratio of 90% or more.

Abstract: The present invention relates to a novel bioactivity testing structure for single cell tracking using a gelling agent and a bioactivity testing system including the testing structure. The present invention also relates to bioactivity testing, drug susceptibility testing, antibiotic screening, and diagnostic methods using the testing structure. The bioactivity testing structure of the present invention enables very rapid and simple drug susceptibility testing of bacteria, particularly Mycobacterium tuberculosis, drug screening, and bacterial diagnosis. Particularly, the use of the testing structure enables DST and diagnosis of bacteria only by pretreatment without the need to concentrate human sputum samples irrespective of inoculum effect, ensuring rapid, accurate, and simple testing compared to conventional tuberculosis diagnosis or DST systems. In addition, the testing structure of the present invention simultaneously enables the diagnosis and drug susceptibility testing of tuberculosis.

Abstract: The present invention relates to a novel bioactivity testing structure for single cell tracking using a gelling agent and a bioactivity testing system including the testing structure. The present invention also relates to bioactivity testing, drug susceptibility testing, antibiotic screening, and diagnostic methods using the testing structure. The bioactivity testing structure of the present invention enables very rapid and simple drug susceptibility testing of bacteria, particularly Mycobacterium tuberculosis, drug screening, and bacterial diagnosis. Particularly, the use of the testing structure enables DST and diagnosis of bacteria only by pretreatment without the need to concentrate human sputum samples irrespective of inoculum effect, ensuring rapid, accurate, and simple testing compared to conventional tuberculosis diagnosis or DST systems. In addition, the testing structure of the present invention simultaneously enables the diagnosis and drug susceptibility testing of tuberculosis.